


830010-2002.2
09/975,812In the Claims

Please enter the following amendments to the claims:

1-10 (cancelled)

 11. (currently amended) A method of providing topical analgesia to a subject comprising topical administration of a pharmaceutical composition comprising a morphine to lidocaine ratio of about 1:0.1 to about 1:2.4, wherein morphine is in an amount ranging from about 0.01% to about 25%, and lidocaine is in an amount ranging from about 0.01% to about 25%, and a physiologically acceptable topical excipient to potentiate a synergistic antinociceptive response at peripheral sites.

12-16 (cancelled)

17. (previously presented) The method according to claim 11, wherein the morphine is administered in a dose of about 0.1% to about 10%.

18. (previously presented) The method according to claim 11, wherein the morphine is administered in a dose of about 0.5% to about 5%.

19. (previously presented) The method according to claim 11, wherein the morphine is administered in a dose of about 0.01% to about 1%.

20. (previously presented) The method according to claim 11, wherein the morphine is administered in a dose of about 0.01% to about 0.05%.

21-22 (cancelled)

23. (previously presented) The method according to claim 11, wherein the lidocaine is administered in a dose of about 0.1% to about 15%.


830010-2002.2

09/975,812

24. (previously presented) The method according to claim 11, wherein the lidocaine is administered in a dose of about 0.5% to about 5%.

25. (previously presented) The method according to claim 11, wherein the lidocaine is administered in a dose of about 0.01% to about 1%.

26. (previously presented) The method according to claim 11, wherein the lidocaine is administered in a dose of about 0.01% to about 0.05%.

 27-35 (cancelled)

36. (new) A method of providing topical analgesia to a subject comprising topical administration of a pharmaceutical composition comprising morphine and lidocaine, in a morphine to lidocaine ratio of about 1:0.1 to about 1:2.4, and a physiologically acceptable topical excipient to potentiate a synergistic antinociceptive response at peripheral sites.

37. (new) A method of producing a synergistic antinociceptive response in a subject at a peripheral site comprising topical administration of a pharmaceutical composition comprising morphine, lidocaine and a physiologically acceptable topical excipient, wherein the ED₅₀ ratio of morphine to lidocaine is about 1:0.2 to about 1:3.6.
